Prolactin-induced mammary tumorigenesis is not a rodent-specific response

Toxicologic Pathology

Volumn 39, Issue 6, 2011, Pages 1020-1022

  Harvey, Philip W ^a  

^a Department of Genetic and Molecular Toxicology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR BLOCKING AGENT; PROLACTIN; PROLACTIN RECEPTOR;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER RISK; HYPERPROLACTINEMIA; LETTER; MAMMOGRAPHY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL;

ANIMALS; CARCINOGENICITY TESTS; CARCINOGENS; FEMALE; HUMANS; MALE; MUTAGENICITY TESTS;

RODENTIA;

EID: 80053584864     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623311419526     Document Type: Letter

References (33)

1. Ben-Jonathan N., Liby K., McFarland M., Zinger M.. Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol Metab. 2002 ; 13: 245-50 (Pubitemid 36733969)
2. Bostwick J. R., Guthrie S. K., Ellingrod V. L.. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy. 2009 ; 29: 64-73
3. Carver K. C., Arendt L. M., Schuler L. A.. Complex prolactin crosstalk in breast cancer: New therapeutic implications. Mol Cell Endocrinol. 2009 ; 307: 1-7
4. Clevenger C. V.. Role of prolactin/prolactin receptor signaling in human breast cancer. Breast Dis. 2003 ; 18: 75-86 (Pubitemid 39193333)
5. Clevenger C. V., Furth P. A., Hankinson S. E., Schuler L. A.. The role of prolactin in mammary carcinoma. Endocr Rev. 2003 ; 24: 1-27 (Pubitemid 36223277)
6. Clevenger C. V., Gadd S. L., Zheng J.. New mechanisms for PRLr action in breast cancer. Trends Endocrinol Metab. 2009 ; 20: 223-9
7. Clevenger C. V., Zheng J., Jablonski E. M., Galbaugh T. L., Fang F.. From bench to bedside: Future potential for the translation of prolactin inhibitors as breast cancer therapeutics. J Mammary Gland Biol Neoplasia. 2008 ; 13: 147-56
8. Das R., Vonderhaar B. K.. Prolactin as a mitogen in mammary cells. J Mammary Gland Biol Neoplasia. 1997 ; 2: 29-39 (Pubitemid 127717410)
9. Eliassen A. H., Tworoger S. S., Hankinson S. E.. Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in premenopausal and postmenopausal women. Int J Cancer. 2007 ; 120: 1536-41 (Pubitemid 46355390)
10. Goffin V., Bernichtein S., Touraine P., Kelly P. A.. Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev. 2005 ; 26: 400-22 (Pubitemid 40686651)
11. Goffin V., Touraine P., Culler M. D., Kelly P. A.. Drug insight: Prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia?. Nat Clin Pract Endocrinol Metab. 2006 ; 2: 571-81 (Pubitemid 44536605)
12. Goodman G., Bercovich D.. Prolactin does not cause breast cancer and may prevent it or be therapeutic in some conditions. Med Hypotheses. 2008 ; 70: 244-51
13. Greendale G. A., Huang M. H., Ursin G., Ingles S., Stanczyk F., Crandall C., Laughlin G. A., Barrett-Connor E., Karlamangla A.. Serum prolactin levels are positively associated with mammographic density in postmenopausal women. Breast Cancer Res Treat. 2007 ; 105: 337-46 (Pubitemid 47596443)
14. Hankinson S. E., Willett W. C., Michaud D. S., Manson J. E., Colditz G. A., Longcope C., Rosner B., Speizer F. E.. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1999 ; 91: 629-34 (Pubitemid 29194050)
15. Harvey P. W.. Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: Prolactin involvement in human breast cancer and significance for toxicology risk assessments. J Appl Toxicol. 2005 ; 25: 179-83 (Pubitemid 40806337)
16. Harvey P. W., Everett D. J.. Regulation of endocrine-disrupting chemicals: Critical overview and deficiencies in toxicology and risk assessment for human health. Best Pract Res Clin Endocrinol Metab. 2006 ; 20: 145-65 (Pubitemid 43323768)
17. Harvey P. W., Everett D. J., Springall C. J.. Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: Role in breast and prostate cancer. Hum Exp Toxicol. 2006 ; 25: 395-404 (Pubitemid 44139566)
18. Harvey P. W., Everett D. J., Springall C. J.. Adverse effects of prolactin in rodents and humans: Breast and prostate cancer. J Psychopharmacol. 2008 ; 22: 20-7
19. Howell S. J., Anderson E., Hunter T., Farnie G., Clarke R. B.. Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity. Breast Cancer Res. 2008 ; 10: R68
20. Jacobson E. M., Hugo E. R., Borcherding D. C., Ben-Jonathan N.. Prolactin in breast and prostate cancer: Molecular and genetic perspectives. Discov Med. 2011 ; 59: 315-24
21. Jacobson E. M., Hugo E. R., Tuttle T. R., Papoian R., Ben-Jonathan N.. Unexploited therapies in breast cancer and prostate cancer: Blockade of the prolactin receptor. Trends Endocrinol Metab. 2010 ; 21: 691-8
22. Liby K., Neltner B., Mohamet L., Menchen L., Ben-Jonathan N.. Prolactin overexpression by MDA-MB-435 human breast cancer cells accelerates tumor growth. Breast Cancer Res Treat. 2003 ; 79: 241-52 (Pubitemid 36649174)
23. Perks C. M., Keith A. J., Goodhew K. L., Savage P. B., Winters Z. E., Holly J. M.. Prolactin acts as a potent survival factor for human breast cancer cell lines. Br J Cancer. 2004 ; 91: 305-11 (Pubitemid 39037076)
24. Peveler R. C., Branford D., Citrome L., Dinan T., Fitzgerald P., Harvey P. W., Holt R. I. G., Howard L., Kohen D., Jones I., O'Keane V., Pariente C., Pendlebury J., Smith S, Yeomans D.. Antipsychotics and hyperprolactinaemia: Clinical recommendations. J Psychopharmacol. 2008 ; 22 ((Suppl.)). 20-7
25. Schroeder M. D., Symowicz J., Schuler L. A.. PRL modulates cell cycle regulators in mammary tumour epithelial cells. Mol Endocrinol. 2002 ; 16: 45-57 (Pubitemid 34044497)
26. Scotti M. L., Langenheim J. F., Tomblyn S., Springs A. E., Chen W. Y.. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells. Breast Cancer Res Treat. 2008 ; 111: 241-50
27. Tworoger S. S., Eliassen A. H., Rosner B., Sluss P., Hankinson S. E.. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res. 2004 ; 64: 6814-9 (Pubitemid 39297946)
28. Tworoger S. S., Eliassen A. H., Sluss P., Hankinson S. E.. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol. 2007 ; 25: 1482-8 (Pubitemid 46733075)
29. Tworoger S. S., Hankinson S. E.. Prolactin and breast cancer risk. Cancer Lett. 2006 ; 243: 160-9 (Pubitemid 44485858)
30. Tworoger S. S., Hankinson S. E.. Prolactin and breast cancer etiology: An epidemiologic perspective. J Mammary Gland Biol Neoplasia. 2008 ; 13: 41-53
31. Tworoger S. S., Sluss P., Hankinson S. E.. Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res. 2006 ; 66: 2476-82
32. Vonderhaar B. K.. Estrogens are not required for prolactin induced growth of MCF-7 human breast cancer cells. Cancer Lett. 1989 ; 47: 105-10 (Pubitemid 19238149)
33. Wang P. S., Walker A. M., Tsuang M. T., Orav E. J., Glynn R. J., Levin R., Avorn J.. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry. 2002 ; 59: 1147-54 (Pubitemid 35424025)